Hapvida stock gains 17.18 percent on hospital asset plan

Published on 10/05/2026 at 19:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hapvida stock is tied to a potential BRL 1.5 billion sale-leaseback reported on October 2, 2026. Q2 revenue rose 55.1 percent, while EBITDA margin fell to 56.7 percent.

Hapvida, BRHAPVACNOR4, Illustration mit AI erstellt.

Hapvida stock (ISIN BRHAPVACNOR4) was trading at BRL 9.14 on B3 on October 5, 2026 at 1:48 p.m. BRT, up 17.18 percent from the prior close. The move follows a report that the healthcare operator is considering a hospital sale-leaseback worth up to BRL 1.5 billion.

Hospital assets drive the move

According to El Fondo on October 2, 2026, Hapvida hired banks to structure a possible sale-leaseback involving part of its hospital portfolio. The structure would allow Hapvida to keep operating the properties while directing proceeds toward debt repayment.

Valor Investe reported on October 2, 2026, that Jefferies viewed the transaction as a potential liquidity and deleveraging catalyst. The report identified Jefferies analyst Antonio Pedro Cardoso and cited a BRL 19 price target, but the transaction remains a potential plan rather than a completed asset sale.

Growth meets margin pressure

Hapvida's second-quarter 2026 revenue rose 55.1 percent year over year to USD 240.022 million, while EBITDA increased 36.0 percent to USD 136.179 million, according to Frontier Market overview on September 16, 2026. The figures show strong reported sales growth, but the operating conversion weakened.

EBITDA margin fell to 56.7 percent in Q2 2026 from 64.7 percent in Q2 2025, a decline of 8.0 percentage points. The same report said Hapvida posted a USD 14.933 million net loss in Q2 2026, compared with a USD 59.46 million loss a year earlier.

Consensus target stays above price

According to Fintel on October 2, 2026, the average one-year analyst target was revised to BRL 10.52 from BRL 11.79. The average target is 15.1 percent above the BRL 9.14 price on October 5, 2026, while published targets span BRL 6.56 to BRL 19.95.

Fintel listed 16 recommendations as of September 1, 2026: 1 strong buy, 10 holds, 2 sells and 3 strong sells, alongside 3 strong sell ratings. The distribution places the operating recovery and the proposed asset monetization at the center of the stock debate.

Hapvida stock trades at BRL 9.14

Hapvida stock was last at BRL 9.14 on B3 on October 5, 2026 at 1:48 p.m. BRT, with volume of 12,317,200 shares. Its 52-week range was BRL 6.01 to BRL 36.53, while market capitalization stood at BRL 4.3 billion on the same date.